- Revenue of $44.8 million; 49% growth over 3Q 2009; Pro Forma
Revenue Growth of 2% over 3Q 2009 and 2.3% Growth on a
Constant-Currency Basis
- Adjusted EBITDA of $5.3 million; 11.9% growth over 3Q 2009
- Non-GAAP Net Earnings of $0.7 million; or $0.01 per share
Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of
Alphatec Spine, Inc., a medical device company that designs,
develops, manufactures and markets products for the surgical
treatment of spine disorders, with a focus on treating conditions
related to the aging spine, announced today financial results for
the fiscal quarter ended September 30, 2010.
Third Quarter 2010 Performance
Highlights
- Achieved US revenues of $30.0 million, representing 15.2%
year-over-year growth on a GAAP basis, and 3.4% year-over-year
growth on a pro forma basis.
- Launched PureGen™, the Company's Osteoprogenitor Cell Allograft
with the first case completed in September.
- Established Biologics Division at Alphatec Spine, with the
addition of Edward Ross, Vice President and General Manager,
Biologics as well as dedicated sales specialists to drive biologics
product adoption and work with customers as biologics experts.
- Strengthened US sales network with the addition of several
independent distribution agents and direct representatives in key
strategic markets.
- OsseoFix™, the Company's proprietary device for treating
vertebral compression fractures and restoration of vertebral
height, has been used in over 1,600 patients in Europe through 3Q
2010, representing continued acceleration in product adoption.
- OsseoScrew™, the Company's proprietary expandable pedicle screw
system, has been used in over 100 patients in Europe through 3Q
2010.
- Helifix™ Interspinous Spacer System, a proprietary minimally
invasive non-fusion solution for lumbar spinal stenosis, was
launched in Europe with the first cases completed in Switzerland
and Germany.
- Solus™ ALIF System, a zero-profile, single-action locking
implant that is used in anterior lumbar interbody fusion (ALIF)
procedures, was launched in Europe with the first cases completed
in Germany.
- The Company resubmitted the Solus 510(k) application with a
revised indication in the third quarter 2010.
Dirk Kuyper, the Company's President and Chief Executive
Officer, stated: "I am proud of the focus of the Alphatec Spine
team and our ability to achieve continued revenue growth through
execution and key product launches despite the challenges currently
facing the spine market." Mr. Kuyper continued, "2010 has been
a transformative year for the Company and in the third quarter we
saw a stabilization of our business internationally and a
stabilization of pricing here in the US. The Scient'x
integration is progressing, and with the launch of PureGen and most
of our key technologies in Europe, we are well positioned as we
enter 2011 to drive towards our goal of being the leading global
pure-play spine company. We have the team, the products and the
strategic plan to achieve long-term revenue growth and enhanced
profitability."
Third Quarter 2010 Financial Review
Consolidated revenues for the third quarter 2010 were $44.8
million, an increase of $14.7 million, or 49.0%, from the $30.1
million reported for the third quarter 2009. U.S. revenues for the
third quarter 2010 were $30.0 million, an increase of 15.2% from
the $26.1 million reported for the third quarter 2009.
Gross profit for the third quarter 2010 was $28.9 million, an
increase of $8.8 million, or 44.1% over the third quarter 2009
gross profit of $20.1 million. The third quarter 2010 gross margin
of 64.5% was below the third quarter 2009 gross margin of 66.7%,
primarily due to geographic sales mix associated with our increased
international business. The third quarter gross margin of
64.5% was higher than the second quarter 2010 gross margin of
63.5%, reflecting increased manufacturing efficiencies and reduced
royalty burden.
Total operating expenses for the third quarter 2010 were $32.4
million, which included $2.4 million of in-process research and
development expenses, $5.2 million in operating expenses associated
with the addition of the Company's acquired international
operations and $0.7 million of restructuring expenses. Total
operating expenses for the third quarter 2009 were $20.9 million
and included $1.2 million in acquisition-related expenses.
Adjusted EBITDA was $5.3 million for the third quarter 2010, an
increase of $0.6 million compared to adjusted EBITDA of $4.7
million reported for the third quarter 2009. Adjusted EBITDA
for the third quarter 2009 included $1.2 million of Scient'x
acquisition-related expenses previously recorded in general and
administrative expenses.
Net loss for the third quarter 2010 was $3.8 million, or ($0.04)
per share (basic and diluted), compared with a net loss of $1.3
million, or ($0.02) per share (basic and diluted) for the third
quarter 2009.
Non-GAAP EPS for the third quarter 2010 was $0.01 per share
compared to $0.00 per share reported in the third quarter 2009.
Non-GAAP EPS excludes the impact of in-process research and
development expenses, Scient'x acquisition-related expenses and
restructuring expenses.
Cash and cash equivalents were $28.9 million at September 30,
2010. In October 2010, the Company amended and restated its loan
agreement with Silicon Valley Bank, and the agreement provides for
a $32 million working capital revolving line of credit. The loan
agreement provides a significant reduction in debt service and
terminates the principal payments that existed in the prior credit
facility. The proceeds from the new loan agreement will primarily
be used to pay off the Company's existing credit facility with
Silicon Valley Bank and Oxford Finance Corporation.
Updated Full Year 2010 Financial Guidance
Due to continuing uncertainty in the US spine market as it
relates to procedure volumes, in addition to international debt and
solvency issues impacting government-funded health systems, the
Company is adjusting its full-year 2010 guidance as follows:
- GAAP annual revenues of $170 million to $172 million; a
reduction from the $177 million to $182 million previously
announced
- Pro forma annual revenues of $181 million to $183 million; a
reduction from the $188 million to $193 million previously
announced
- Adjusted EBITDA of $19 million to $20 million; a reduction from
the $21 million to $24 million previously announced
The revised annual pro forma revenue guidance reflects annual
growth of 6% to 7% over pro forma 2009 revenues of $170.8
million.
Conference Call
Alphatec Spine will host a conference call today at 2:00 p.m. PT
/ 5:00 p.m. ET to discuss the results. To participate in the
conference call, please visit the investor relations section of the
Alphatec Spine website at www.alphatecspine.com. The dial-in
numbers are (877) 556-5251 for domestic callers and (720) 545-0036
for international callers. A live webcast of the conference call
will be available online on the investor relations section of the
Alphatec Spine website at www.alphatecspine.com. The webcast will
be recorded and will remain available on the investor relations
section of Alphatec Spine's website for at least 30 days.
About Alphatec Spine
Alphatec Spine, Inc. is a wholly owned subsidiary of Alphatec
Holdings, Inc. (Nasdaq:ATEC). Alphatec Spine is a medical device
company that designs, develops, manufactures and markets products
for the surgical treatment of spine disorders, primarily focused on
the aging spine. The Company's mission is to combine world-class
customer service with innovative, surgeon-driven design that will
help improve the aging patient's quality of life. The Company is
poised to achieve its goal through new solutions for patients with
osteoporosis, stenosis and other aging spine deformities, improved
minimally invasive products and techniques and integrated biologics
solutions. In addition to its US operations, the Company also
markets its products in over 50 international markets through its
subsidiary, Scient'x SA, via a direct sales force in France, Italy
and the United Kingdom and via independent distributors in the rest
of Europe, the Middle East and Africa, South America and Latin
America. In Asia and Australia, the Company markets its products
through its subsidiary, Alphatec Pacific, Inc, and through
Scient'x's distributors in China, Korea and Australia.
Also visit the Aging Spine Center, www.agingspinecenter.com, a
web-based information portal for healthcare providers and patients
regarding aging spine disorders and their treatment. Alphatec Spine
is working with the National Osteoporosis Foundation as well as
other clinical portals that provide peer-reviewed content, to
populate the Aging Spine Center. The interactive website
enables patients to review pertinent information about all the key
disorders that affect the aging spine in an easy-to-understand
format that includes videos, graphics and questions that should be
asked of caregivers. Medical information includes published
abstracts regarding the aging spine.
The Alphatec Holdings, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3520
Non-GAAP Information for non-GAAP earnings and Adjusted
EBITDA
Non-GAAP earnings included in this press release is a non-GAAP
(generally accepted accounting principles) financial measure that
represents net income (loss) excluding the effects of in-process
research and development expenses, acquisition-related expenses,
restructuring expenses and litigation settlement expenses.
Management does not consider these expenses when it makes certain
evaluations of the operations of the Company. Non-GAAP earnings, as
defined above, may not be similar to non-GAAP earnings measures
used by other companies and is not a measurement under GAAP.
Adjusted EBITDA included in this press release is a non-GAAP
financial measure that represents net income (loss) excluding the
effects of interest, taxes, depreciation, amortization, stock-based
compensation expense, and other income or expense items, such as
in-process research and development expense and acquisition-related
expenses. Adjusted EBITDA, as defined above, may not be similar to
adjusted EBITDA measures used by other companies and is not a
measurement under GAAP.
Though management finds non-GAAP-based earnings or loss and
adjusted EBITDA useful for evaluating aspects of the Company's
business, its reliance on these measures are limited because
excluded items often have a material effect on the Company's
earnings and earnings per common share calculated in accordance
with GAAP. The Company believes that non-GAAP earnings and adjusted
EBITDA provides investors with an additional tool for evaluating
the Company's core performance, which management uses in its own
evaluation of continuing operating performance, and a base-line for
assessing the future earnings potential of the Company. While the
GAAP results are more complete, the Company prefers to allow
investors to have these supplemental metrics since, with
reconciliation to GAAP, they may provide greater insight into the
Company's financial results.
Forward Looking Statements
This press release may contain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve risks and uncertainty. Such statements are
based on management's current expectations and are subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These forward-looking statements include, but are not
limited to: Alphatec Spine's ability to accelerate new product
momentum, bring to market differentiated products and commercialize
its product pipeline. Alphatec Spine cautions investors that there
can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such
forward-looking statements as a result of various factors,
including, but not limited to, the following: Alphatec Spine's
ability to meet its 2010 revenue, adjusted EBITDA, and earnings
projections, the ability to successfully integrate Scient'x and
Alphatec, the US and global growth rate of the spine market overall
and the growth rate related to aging and elderly patients, the
impact of macroeconomic conditions on the spine market both inside
the US and outside of the US, the negative impact of pricing
reductions in the spine market, uncertainty of success in
developing new products or products currently in Alphatec Spine's
pipeline, the successful global launch of the Alphatec Spine's new
products and the products in its development pipeline including
PureGen, HeleFix, OsseoFix, OsseoScrew, and Solus, failure to
achieve acceptance of Alphatec Spine's products by the surgeon
community, failure to obtain FDA clearance or approval for new
products, or unexpected or prolonged delays in the process,
Alphatec Spine's ability to develop and expand its business in the
United States, Asia, Europe, the Middle East and Africa and Latin
America continuation of favorable third party payor reimbursement
for procedures performed using Alphatec Spine's products, price
erosion, unanticipated expenses or liabilities or other adverse
events affecting cash flow or Alphatec Spine's ability to
successfully control its costs or achieve profitability,
uncertainty of additional funding, Alphatec Spine's ability to
compete with other competing products and with emerging new
technologies, product liability exposure, patent infringement
claims and claims related to Alphatec Spine's or a third party's
intellectual property. Please refer to the risks detailed from time
to time in Alphatec Spine's SEC reports, including quarterly
reports on Form 10-Q, reports on Form 8-K and annual reports on
Form 10-K. Alphatec Spine disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events, or otherwise, unless
required by law.
ALPHATEC HOLDINGS,
INC. |
CONDENSED CONSOLIDATED
BALANCE SHEETS |
(in thousands -
unaudited) |
|
|
|
|
September 30, 2010 |
December 31, 2009 |
ASSETS |
|
|
Current assets: |
|
|
Cash and cash equivalents |
$ 28,854 |
$ 10,085 |
Accounts receivable, net |
43,151 |
24,766 |
Inventories, net |
53,552 |
29,515 |
Prepaid expenses and other current
assets |
5,851 |
3,128 |
Deferred income tax assets |
1,817 |
128 |
Total current assets |
133,225 |
67,622 |
|
|
|
Property and equipment, net |
39,415 |
30,356 |
Goodwill |
172,318 |
60,113 |
Intangibles, net |
42,354 |
2,296 |
Other assets |
3,081 |
1,501 |
Total assets |
$ 390,393 |
$ 161,888 |
|
|
|
LIABILITIES AND STOCKHOLDERS'
EQUITY |
|
|
Current liabilities: |
|
|
Accounts payable |
$ 19,272 |
$ 12,781 |
Accrued expenses |
24,580 |
16,439 |
Deferred revenue |
2,984 |
2,135 |
Other current liabilities |
1,033 |
-- |
Current portion of long-term
debt |
10,147 |
6,724 |
Total current liabilities |
58,016 |
38,079 |
|
|
|
Total long term liabilities |
39,191 |
25,377 |
Redeemable preferred stock |
23,603 |
23,603 |
Stockholders' equity -
Alphatec |
269,043 |
74,829 |
Non-controlling interest |
540 |
-- |
Total liabilities and stockholders'
equity |
$ 390,393 |
$ 161,888 |
|
|
ALPHATEC HOLDINGS,
INC. |
CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS |
(in thousands,
except per share amounts - unaudited) |
|
|
|
|
|
|
Three Months Ended September
30, |
Nine Months Ended September
30, |
|
2010 |
2009 |
2010 |
2009 |
|
|
|
|
|
Revenues |
$ 44,846 |
$ 30,103 |
$ 125,592 |
$ 87,358 |
Cost of revenues |
15,546 |
10,028 |
43,516 |
28,311 |
Amortization of acquired intangible
assets |
373 |
-- |
742 |
-- |
Total cost of revenues |
15,919 |
10,028 |
44,258 |
28,311 |
Gross profit |
28,927 |
20,075 |
81,334 |
59,047 |
|
|
|
|
|
Operating expenses: |
|
|
|
|
Research and development |
3,751 |
3,630 |
12,347 |
9,933 |
In-process research and development |
2,425 |
50 |
2,967 |
5,833 |
Sales and marketing |
17,052 |
12,088 |
47,571 |
36,618 |
General and administrative |
7,933 |
3,895 |
21,500 |
15,216 |
Amortization of acquired intangible
assets |
533 |
-- |
1,002 |
-- |
Transaction related expenses |
6 |
1,240 |
3,651 |
1,240 |
Restructuring expenses |
702 |
-- |
2,389 |
-- |
Total operating expenses |
32,402 |
20,903 |
91,427 |
68,840 |
Operating loss |
(3,475) |
(828) |
(10,093) |
(9,793) |
Interest and other income (expense),
net |
(1,085) |
(630) |
(2,363) |
(2,508) |
Loss from continuing operations before
taxes |
(4,560) |
(1,458) |
(12,456) |
(12,301) |
Income tax benefit |
(770) |
(94) |
(899) |
(68) |
Loss from continuing operations |
(3,790) |
(1,364) |
(11,557) |
(12,233) |
Income from discontinued operations, net
of tax |
-- |
81 |
78 |
264 |
|
|
|
|
|
Net loss |
$ (3,790) |
$ (1,283) |
$ (11,479) |
$ (11,969) |
|
|
|
|
|
Net loss attributable to non-controlling
interest |
$ -- |
$ -- |
$ -- |
$ -- |
Net loss attributable to Alphatec |
$ (3,790) |
$ (1,283) |
$ (11,479) |
$ (11,969) |
|
|
|
|
|
Net income (loss) per common share: |
|
|
|
|
Basic and diluted net loss from
continuing operations |
$ (0.04) |
$ (0.02) |
$ (0.15) |
$ (0.25) |
Basic and diluted net income from
discontinued operations |
-- |
0.00 |
0.00 |
0.00 |
Basic and diluted net loss per share |
$ (0.04) |
$ (0.02) |
$ (0.15) |
$ (0.25) |
|
|
|
|
|
Weighted-average shares - basic and
diluted |
86,990 |
51,516 |
75,394 |
48,411 |
|
|
ALPHATEC HOLDINGS,
INC. |
RECONCILIATION OF
NON-GAAP FINANCIAL MEASURES |
(in thousands -
unaudited) |
|
|
|
|
|
|
Three Months Ended September
30, |
Nine Months Ended September
30, |
|
2010 |
2009 |
2010 |
2009 |
|
|
|
|
|
Operating loss, as reported |
$ (3,475) |
$ (828) |
$ (10,093) |
$ (9,793) |
Add back: |
|
|
|
|
Depreciation |
3,586 |
2,292 |
9,462 |
6,234 |
Amortization of intangibles |
122 |
854 |
1,245 |
2,410 |
Amortization of acquired intangibles |
906 |
-- |
1,744 |
-- |
Total EBITDA |
1,139 |
2,318 |
2,358 |
(1,149) |
|
|
|
|
|
Add back significant items: |
|
|
|
|
Stock-based compensation |
573 |
1,098 |
2,326 |
2,563 |
In-process research and development |
2,425 |
50 |
2,967 |
5,833 |
Acquisition-related inventory
step-up |
419 |
-- |
832 |
-- |
Transaction related expenses |
6 |
1,240 |
3,651 |
1,240 |
Restructuring expenses |
702 |
-- |
2,389 |
-- |
|
|
|
|
|
EBITDA, as adjusted for significant
items |
$ 5,264 |
$ 4,706 |
$ 14,523 |
$ 8,487 |
|
|
|
|
|
|
|
|
|
|
Net loss, as reported |
$ (3,790) |
$ (1,283) |
$ (11,479) |
$ (11,969) |
Add back: |
|
|
|
|
In-process research and development |
2,425 |
50 |
2,967 |
5,833 |
Acquisition-related inventory
step-up |
419 |
-- |
832 |
-- |
Amortization of acquired intangibles |
906 |
-- |
1,744 |
-- |
Transaction related expenses |
6 |
1,240 |
3,651 |
1,240 |
Restructuring expenses |
702 |
-- |
2,389 |
-- |
|
|
|
|
|
Net loss, as adjusted for significant
items |
$ 668 |
$ 7 |
$ 104 |
$ (4,896) |
|
|
|
|
|
|
|
|
|
|
Net loss per common share - basic and
diluted |
$ (0.04) |
$ (0.02) |
$ (0.15) |
$ (0.25) |
Add back: |
|
|
|
|
In-process research and development |
0.03 |
0.00 |
0.04 |
0.12 |
Acquisition-related inventory
step-up |
0.00 |
-- |
0.01 |
-- |
Amortization of acquired intangibles |
0.01 |
-- |
0.02 |
-- |
Transaction related expenses |
0.00 |
0.02 |
0.05 |
0.03 |
Restructuring expenses |
0.01 |
-- |
0.03 |
-- |
|
|
|
|
|
Net loss per common share - basic
and diluted, as adjusted for significant items |
$ 0.01 |
$ 0.00 |
$ 0.00 |
$ (0.10) |
|
|
|
|
|
|
ALPHATEC HOLDINGS,
INC. |
RECONCILIATION OF
GEOGRAPHIC SEGMENT REVENUES AND GROSS PROFIT |
(in thousands, except
gross profit margin percentages - unaudited) |
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September
30, |
|
|
|
2010 |
2009 |
% Change |
Impact from Foreign Currency |
|
|
|
|
|
Revenues by geographic segment |
|
|
|
|
U.S. |
$ 30,010 |
$ 26,052 |
15.2% |
0.0% |
Europe |
5,770 |
1,036 |
456.9% |
-4.4% |
Asia |
6,020 |
3,015 |
99.7% |
4.7% |
Rest of world |
3,046 |
-- |
100.0% |
-4.4% |
Total revenues |
$ 44,846 |
$ 30,103 |
49.0% |
-0.3% |
|
|
|
|
|
Gross profit by geographic segment |
|
|
|
|
U.S. |
$ 23,346 |
$ 17,937 |
|
|
Europe |
1,595 |
412 |
|
|
Asia |
3,143 |
1,726 |
|
|
Rest of world |
843 |
-- |
|
|
Total gross profit |
$ 28,927 |
$ 20,075 |
|
|
|
|
|
|
|
Gross profit margin by geographic
segment |
|
|
|
|
U.S. |
77.8% |
68.9% |
|
|
Europe |
27.6% |
39.8% |
|
|
Asia |
52.2% |
57.2% |
|
|
Rest of world |
27.7% |
0.0% |
|
|
Total gross profit margin |
64.5% |
66.7% |
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September
30, |
|
|
|
2010 |
2009 |
% Change |
Impact from Foreign Currency |
|
|
|
|
|
Revenues by geographic segment |
|
|
|
|
U.S. |
$ 87,763 |
$ 76,243 |
15.1% |
0.0% |
Europe |
18,543 |
2,415 |
667.8% |
-5.4% |
Asia |
14,265 |
8,700 |
64.0% |
1.2% |
Rest of world |
5,021 |
-- |
100.0% |
-5.4% |
Total revenues |
$ 125,592 |
$ 87,358 |
43.8% |
-0.9% |
|
|
|
|
|
Gross profit by geographic segment |
|
|
|
|
U.S. |
$ 64,145 |
$ 53,100 |
|
|
Europe |
7,279 |
965 |
|
|
Asia |
7,905 |
4,982 |
|
|
Rest of world |
2,005 |
-- |
|
|
Total gross profit |
$ 81,334 |
$ 59,047 |
|
|
|
|
|
|
|
Gross profit margin by geographic
segment |
|
|
|
|
U.S. |
73.1% |
69.6% |
|
|
Europe |
39.3% |
40.0% |
|
|
Asia |
55.4% |
57.3% |
|
|
Rest of world |
39.9% |
0.0% |
|
|
Total gross profit margin |
64.8% |
67.6% |
|
|
|
|
|
|
|
|
|
|
|
|
Footnotes: |
1) IMC operating results
have been removed from Asia revenues and gross profit for 2010 and
2009 periods presented. |
|
|
|
|
|
2) The impact from foreign
currency represents the percentage change in 2010 revenues due to
the change in foreign exchange rates for the periods
presented. |
|
|
ALPHATEC HOLDINGS,
INC. |
PRO FORMA REVENUES BY
GEOGRAPHIC SEGMENT |
(in thousands -
unaudited) |
|
|
|
|
|
|
Three Months Ended September
30, |
% Change |
|
|
2010 |
2009 |
Reported |
Constant Currency |
|
|
|
|
|
Pro Forma Revenues by geographic segment |
|
|
|
|
U.S. |
$ 30,010 |
$ 29,034 |
3.4% |
3.4% |
Europe |
5,770 |
6,813 |
-15.3% |
-11.4% |
Asia |
6,020 |
4,856 |
24.0% |
18.4% |
Rest of world |
3,046 |
3,246 |
-6.2% |
-1.8% |
Total revenues |
$ 44,846 |
$ 43,949 |
2.0% |
2.3% |
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September
30, |
% Change |
|
|
2010 |
2009 |
Reported |
Constant Currency |
|
|
|
|
|
Pro Forma Revenues by geographic segment |
|
|
|
|
U.S. |
$ 90,738 |
$ 84,607 |
7.2% |
7.2% |
Europe |
23,398 |
17,520 |
33.6% |
39.6% |
Asia |
15,924 |
13,670 |
16.5% |
15.3% |
Rest of world |
6,867 |
8,417 |
-18.4% |
-15.0% |
Total revenues |
$ 136,927 |
$ 124,214 |
10.2% |
11.2% |
|
|
|
|
|
|
|
|
|
|
Footnotes: |
1) IMC operating results
have been removed from Asia pro forma revenues for 2010 and 2009
periods presented. |
|
|
|
|
|
2) Pro Forma revenues for
all perods presented include the results of Scient'x as if the
Scient'x acquisition had occurred on January 1, 2009. |
|
|
|
|
|
3) % Change - Constant
Currency represents the change in 2010 pro forma revenue had the
2010 foreign exchange rates remained constant with 2009 foreign
exchange rates. |
CONTACT: Alphatec Spine, Inc.
Michael O'Neill, Chief Financial Officer
(760) 494-6746
investorrelations@alphatecspine.com
Westwicke Partners
Lynn C. Pieper
(415) 202-5678
lynn.pieper@westwicke.com
Alphatec (NASDAQ:ATEC)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Alphatec (NASDAQ:ATEC)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024